Last €151.57 EUR
Change Today -1.58 / -1.03%
Volume 0.0
BR6 On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 1:03 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

cr bard inc (BR6) Snapshot

Open
€151.88
Previous Close
€153.16
Day High
€152.44
Day Low
€151.33
52 Week High
01/23/15 - €159.88
52 Week Low
04/25/14 - €98.02
Market Cap
11.3B
Average Volume 10 Days
14.1
EPS TTM
--
Shares Outstanding
74.3M
EX-Date
01/22/15
P/E TM
--
Dividend
€0.87
Dividend Yield
0.45%
Current Stock Chart for CR BARD INC (BR6)

cr bard inc (BR6) Related Businessweek News

No Related Businessweek News Found

cr bard inc (BR6) Details

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters for the treatment of peripheral vascular disease and heart arrhythmias. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia. In addition, the company offers oncology products that include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders. Further, it provides surgical specialty products comprising implanted grafts and fixation devices for hernia and soft tissue repairs; and hemostats and surgical sealants, as well as other products, such as irrigation, wound drainage, and original equipment manufacturers’ products. The company sells its products directly to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey.

13,900 Employees
Last Reported Date: 02/18/15
Founded in 1907

cr bard inc (BR6) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.1M
President, Chief Operating Officer and Direct...
Total Annual Compensation: $887.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $540.0K
Group President
Total Annual Compensation: $660.0K
Group President
Total Annual Compensation: $560.0K
Compensation as of Fiscal Year 2013.

cr bard inc (BR6) Key Developments

Boston Scientific and C. R. Bard Announce Distribution Agreement for Lutonix® Drug Coated Balloon

Boston Scientific Corporation and C. R. Bard Inc. announced that Boston Scientific will distribute the Lutonix® 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB) in the United States under a limited distribution agreement reached with Bard. This agreement is designed to expand the reach of the Lutonix DCB and will afford more patients suffering from peripheral artery disease an opportunity to benefit from this innovative technology and clinically-proven therapy.

CR Bard Inc. Provides Earnings Guidance for the First Quarter and Full Year 2015

CR Bard Inc. provides earnings guidance for the first quarter and full year 2015. For the quarter, The company expects constant currency sales growth between 4% and 5% and adjusted cash EPS between $2.04 and $2.08. As for capital expenditures, the company expects 2015 to be similar to 2014, between $120 million and $140 million and expects operating cash flow to be in the $700 million range again in 2015. The company expects the effective tax rate to improve again, this time, between 0 and 50 basis points for the full year and this does assume the renewal of the R&D tax credit for 2015. The company expects the full year organic growth rate to again improve over the full year 2014.

CR Bard Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

CR Bard Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company's net sales were $319,500,000 against $791,300,000 a year ago. Income from operations before income taxes was $174,700,000 against $1,102,700,000 a year ago. Net income was $134,200,000 or $1.72 diluted per share against $667,500,000 or $8.28 diluted per share a year ago. Adjusted earnings were $178.2 million or $2.29 per share against $131.6 million or $3.76 per share a year ago. Adjusted net income available to common shareholders was $175.4 million or $2.29 per diluted share compared to $129.2 million or $1.63 per diluted share a year ago. For the full year, the company's net sales were $3,323,600,000 against $3,049,500,000 a year ago. Income from operations before income taxes was $445,800,000 against $1,213,400,000 a year ago. Net income was $294,500,000 or $3.76 diluted per share against $689,800,000 or $8.39 diluted per share a year ago. Adjusted earnings were $658.4 million or $8.40 per share against $531.1 million or $6.51 per share a year ago. Adjusted net income available to common shareholders was $647.5 million or $8.40 per diluted share compared to $525.4 million or $6.51 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BR6:GR €151.57 EUR -1.58

BR6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $60.08 USD -0.13
DENTSPLY International Inc $53.01 USD -0.63
Edwards Lifesciences Corp $133.02 USD -1.88
Endo International PLC $85.60 USD +0.36
Mettler-Toledo International Inc $314.17 USD -0.49
View Industry Companies
 

Industry Analysis

BR6

Industry Average

Valuation BR6 Industry Range
Price/Earnings 45.5x
Price/Sales 3.9x
Price/Book 7.1x
Price/Cash Flow 43.1x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CR BARD INC, please visit www.crbard.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.